Inmune Bio, Inc.
INMB · XNASCIK 1711754fmd_1KTFRKXGZJ0Y65509MQ8CJX0DJManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2017 to Sep 30, 2026, 36 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | 0 | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Research and development | 0 | 3 | 3 | 6 | 21 | 17 | 20 | 33 | 21 |
| Total operating expenses | 1 | 12 | 8 | 12 | 29 | 26 | 30 | 43 | 47 |
| Operating income | (1) | (12) | (8) | (12) | (29) | (26) | (30) | (43) | (47) |
| Interest expense | – | – | – | – | 1 | 2 | 2 | 1 | 0 |
| Other non-operating income (expense) | 0 | – | 0 | 0 | (1) | (1) | (0) | 1 | 1 |
| Income before taxes | – | – | – | – | – | – | 30 | 42 | 46 |
| Income tax expense | 0 | 0 | – | – | – | – | – | – | – |
| Net income | (1) | (12) | (8) | (12) | (30) | (27) | (30) | (42) | (46) |